LATEST NEWS

Class I Medical Devices Notification

Date: 03/12/2019

On March 1st, 2019, ANVISA published RDC 270 / 2019 in the Brazilian Official Gazette. The new legislation deals with the migration of the cadastro route to the notification route for Class I medical devices (materials, equipment and IVD products). RDC 270/2019 amends RDCs 36 and 40/2015 and shall enter into force as of May 2, 2019.

 

To date, the regularization of Class I medical devices has taken place through the cadastro process. Under the new Resolution, the lowest risk products will be regularized through notification – a simplified system in which there will be no prior technical analysis of the petitions. The publication of the notification is expected within 30 days following the notification’s application and the payment of the ANVISA fee; that’s regardless of any documentary analysis by ANVISA. Only after the granting of the notification number can the product be industrialized or commercialized.

 

Here are some important topics featured in RDC 270/2019:
– The documentation required for the initial request and alteration of Class I medical devices remains the same, only with the change from the cadastro form to the notification form.

– The labels and instructions for use of notified products must comply with the requirements established in RDC 185/2001.- The notified products are exempt from revalidation.

– ANVISA may cancel product notification in such cases when it is proven that the product or the manufacturing process poses a risk to the health of the consumer, the patient, the operator or third parties involved; it’s also the case when information is deemed insufficient or there is an error in the sanitary framework of the notified products.

– The Technical Product Dossier remains mandatory for notified products.
– The notifications, their alterations and other actions will be published exclusively in the ANVISA website, in the section of consultation to regularized products.

– There will be no prior technical analysis of the notification requests; however, ANVISA reserves the right to make documentary evaluations of the notification processes at any time.

– The new legislation applies to the processes awaiting the first manifestation upon its entry into force.
– Class I devices already registered in ANVISA will have their cadastrosautomatically converted into notifications, maintaining the same registration number.

MORE NEWS

07/18/2024
  From June 24 to 28, ANVISA participated in the MDSAP Forum and Regulatory Authority Council (RAC) meeting in Essen, Germany. The event gathered representatives from 27 countries, including regulatory authorities, MDSAP auditing organizations, and industry representatives, with notable attendance from Brazilian associations ABIMED and [...]
07/02/2024
  In force since January 2022, RDC 591/2021, which provides for the Unique Device Identification (UDI) system, was amended by ANVISA just days before the deadline for attributing and affixing UDI to risk class IV devices. The amendment was published in RDC 884/2024 on June 1, 2024, and is already in force. According to ANVISA,... Leia [...]
04/12/2024
Marking a significant advancement in regulatory reliance mechanisms, the National Health Surveillance Agency (ANVISA) published Normative Instruction (IN) 290/2024, on April 8, 2024. This normative introduces an optimized procedure for evaluating and deciding on registration petitions for medical devices previously regulated in recognized [...]
03/22/2024
Important Regulatory Update for Manufacturers under MDSAP in Brazil Today, ANVISA has announced a significant regulatory development with the publication of Resolution RDC 850/2024. This regulation brings forth a crucial amendment concerning the validity period of the Brazilian Good Manufacturing Practices (BGMP) Certificate for manufacturers [...]
01/05/2024
Collegiate Board Resolution (RDC) 837/2023, published by ANVISA on December 15th, 2023, brings updates to the rules regarding clinical investigations with medical devices performed in Brazil. Effective immediately from the publication, this resolution aligns Brazilian practices with international standards, providing clearer guidelines for [...]
12/13/2023
On 11 of December 2023, ANVISA published Collegiate Board Resolution – RDC 830/2023, addressing risk classification, registration procedures, as well as labeling requirements and instructions for use of in vitro diagnostic medical devices (IVDs) in Brazil. The new RDC, effective from June 1, 2024, is a comprehensive revision that consolidates [...]
11/28/2023
Public Consultation No. 1.208 will be open to receive contributions until December 9th. In the dynamic landscape of medical device regulations in Brazil, obtaining the Brazilian Good Manufacturing Practices (BGMP) certification is a mandatory request for manufacturers of Class III and Class IV devices seeking Registro. In a recent move towards [...]
03/01/2023
  Starting today – March 1st 2023 – the new Resolution RDC nº 751/2022  comes into force. The Resolution provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. In order to meet the new requirements and procedures, ANVISA has already [...]
09/22/2022
The Collegiate Board Resolution – RDC 751/2022 was published on the 21st of September 2022, which provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. The new RDC consolidates the risk classification and regularization regimes for all risk [...]